ROP

Oxford Vacmedix announces major milestone for lead cancer vaccine OVM-200

OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for OVM-200 development.   Oxford, UK – 23rd January 2025 Press Release – OVM-200 Drug Product 4 year stability Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, announced today that OVM-200 which was manufactured on contract by Eurofins Amatsi to exacting GMP standards, has bee...
Read More

Oxford Vacmedix licenses OVM-200 to Dx&Vx for South Korea, India and China

Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK – 13th December 2024 Press release – OVM-200 licenced to Dx&Vx Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today the finalisation of a licensing deal for its lead cancer vaccine OVM-200, with its largest shareholder Dx&Vx. The sub-license will grant Dx&Vx rights to develop an...
Read More

Oxford Vacmedix announces lead investment for Series B fund

Lead investment of $3.0 million in Oxford Vacmedix Series B from existing investors. Oxford, UK – 6th November 2024 Press Release – Oxford Vacmedix announces lead investment for Series B fund Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today the lead investment in its Series B fund of $3.0m from existing investors, Dx&Vx of Seoul, South Korea and Mr. Jin of Jia He Hui Investment of Beijing, China. Dx&Vx is OVM’s larges...
Read More

Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition

Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division)   The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping Peptide) technology and its applications to develop therapeutic vaccines to treat cancer. OVM’s lead cancer vaccine, OVM-200, is in Phase 1 cl...
Read More

New publication highlights importance of survivin as target and potential for combination use to treat cancer

A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the publication of a key research paper on its lead cancer vaccine,  OVM-200. The...
Read More

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the successful completion of a Pha...
Read More

In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10

The following publication describes a study developing the ROP-TB antigen for both in vitro IGRA-based TB diagnosis, as well as the in vivo skin test for TB diagnosis in both humans and cattle.  The advantages of the ROP-TB diagnosis are firstly distinguishing Mtb infection from BCG vaccination, and secondly, being suitable for industrial manufacture. Read the full article: ROP-TB Diagnosis By Qing Zhang, Xiong Lu, Liang Gao, Siyu Tao, Yinghua Ge, Daocheng Cui, Renying Zhu, Wenshu Lu, Jian Wang...
Read More
en_GBEnglish